Clinical Trial Update: Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating M701 Bispecific Antibody for malignant ascites caused by advanced epithelial solid tumors. The study is currently Active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• M701 Bispecific Antibody (M701)

Snippet

Sponsor: Wuhan YZY Biopharma Co., Ltd. | Conditions: Malignant Ascites | Phase 3 | Status: ACTIVE_NOT_RECRUITING